Enzyme‐Activated Core–Shell Drug Co‐Crystal Nanoparticles for Targeted Salmonella Clearance and Gut Microbiome Restoration
Small · 2025-12 · 21 (48)
DOI: 10.1002/smll.202504914 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, online erschienen am 14.10.2025. Verfasst von Siying Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sanya Institute of China Agricultural University, Sanya, 572025, P. R. China. Hauptthemen laut MEDLINE: Nanoparticles, Gastrointestinal Microbiome, Salmonella typhimurium, Salmonella. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 66 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Guangdong Major Project of Basic and Applied Basic Research.
Abstract (Originalsprache)
Salmonella Typhimurium—a gut‐colonizing pathogen that invades mucosa and triggers colitis—remains clinically challenging due to host barriers limiting oral antibiotic efficacy. To address this issue, an innovative co‐crystal nanoparticle platform is developed for targeted therapy. This platform consists of PC@Kana@TA nanoparticles (PC@Kana@TA NPs), synthesized through a simple, cost‐effective, and scalable process involving two key steps: 1) self‐assembly of tannic acid (TA) with kanamycin (Kana) to form the antimicrobial core Kana@TA nanoparticles (Kana@TA NPs), enhancing drug stability and bactericidal efficacy; and 2) subsequent coating of Kana@TA NPs with mixed pectin–chitosan (PC) to generate the final PC@Kana@TA NPs. This dual‐layer coating strategy not only provides gastric acid resistance but also enables pectinase‐responsive release in the intestinal tract, thereby significantly improving oral bioavailability compared to conventional formulations. In vitro, Kana@TA NPs exhibit above 70% intracellular Salmonella clearance rate in both the RAW264.7 and Caco‐2 cells. Animal experiments revealed that PC@Kana@TA NPs achieved a 5‐log reduction in luminal Salmonella, with inflammatory cytokine levels nearly returned to baseline. Notably, the relatively beneficial gut bacteria abundance is 30.53% higher than the Kana group. This strategy presents a versatile strategy for nano‐enabled intracellular infection therapies, unlocking new opportunities for drug repurposing and optimization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sanya Institute of China Agricultural University, Sanya, 572025, P. R. China.
- National Key Laboratory of Veterinary Public Health and Safety, Beijing Key Laboratory of Detection Technology for Animal-Derived Food Safety, College of Veterinary Medicine, China Agricultural University, Beijing, 1001…
ORCID-Profile: Xiaowei Ma
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Guangdong Major Project of Basic and Applied Basic Research
- PhD Scientific Research and Innovation Foundation of The Education Department of Hainan Province, Joint Project of the Sanya Yazhou Bay Science and Technology…
- earmarked fund
Zitieren
APA
Huang, S., Wang, T., Sheng, N., Zhang, Q., Xu, X., & Ma, X. (2025). Enzyme‐Activated Core–Shell Drug Co‐Crystal Nanoparticles for Targeted Salmonella Clearance and Gut Microbiome Restoration. Small, 21(48). https://doi.org/10.1002/smll.202504914
Vancouver
Huang S, Wang T, Sheng N, Zhang Q, Xu X, Ma X. Enzyme‐Activated Core–Shell Drug Co‐Crystal Nanoparticles for Targeted Salmonella Clearance and Gut Microbiome Restoration. Small. 2025;21(48). doi:10.1002/smll.202504914
BibTeX
@article{Huang2025,
author = {Huang, Siying and Wang, Tingting and Sheng, Nuo and Zhang, Qiwen and Xu, Xiaolong and Ma, Xiaowei},
title = {Enzyme‐Activated Core–Shell Drug Co‐Crystal Nanoparticles for Targeted Salmonella Clearance and Gut Microbiome Restoration},
journal = {Small},
year = {2025},
volume = {21},
number = {48},
doi = {10.1002/smll.202504914}
}
EUVIMED